Nivolumab Shows Marked Activity in Recurrent Metastatic Gynecologic Cancers
Published: Wednesday, Sep 25, 2019
R. Wendel Naumann, MD
Nivolumab (Opdivo) monotherapy demonstrated promising activity in a small number of patients with recurrent or metastatic cervical, vaginal, and vulvar cancer, according to results of the gynecologic cancer cohort of the phase I/II CheckMate-358 trial (NCT02488759).
... to read the full story